• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

News

Article

Daily Derm Times: July 10, 2025

Key Takeaways

  • Severe alopecia areata is significantly linked to a higher risk of atopic dermatitis, especially in adolescents.
  • The FDA's release of over 200 Complete Response Letters enhances transparency in drug approval processes.
SHOW MORE

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Daily Derm Times logo

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Severe Alopecia Areata Linked to Higher Atopic Dermatitis Risk

A recent study reveals a significant link between alopecia areata severity and increased risk of atopic dermatitis, especially in adolescents.

FDA Opens Access to Over 200 CRLs

FDA enhances transparency by publishing over 200 Complete Response Letters, offering insights into drug approval processes and common deficiencies.

Systemic Therapy for Pediatric Atopic Dermatitis: A Growing Case for Early Intervention

Christopher Bunick, MD, PhD, highlights how dupilumab transforms atopic dermatitis treatment in children, improving health outcomes and quality of life beyond skin symptoms.

Zelsuvmi, First At-Home Prescription Gel for Molluscum Contagiosum, Launches in US

Zelsuvmi is the first FDA-approved at-home treatment for molluscum contagiosum, now available for patients aged ≥1 via retail and mail-order pharmacies.

IL-23 Inhibitor Fails to Improve VASI in Pilot Trial

A pilot study evaluates tildrakizumab's safety and potential in treating stable non-segmental vitiligo, highlighting the need for further research on IL-23 inhibitors.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Videos
© 2025 MJH Life Sciences

All rights reserved.